Sol-Gel Technologies (SLGL) Equity Average (2017)
Sol-Gel Technologies (SLGL) reported Equity Average of -$42.0 million for Q4 2017.
Sol-Gel Technologies (SLGL) Equity Average (2017) Analysis & Trends
Sol-Gel Technologies (SLGL) has 1 years of Equity Average data on file, last reported at -$42.0 million in Q4 2017.
- Equity Average for Q4 2017 came in at -$42.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2017 was -$42.0 million (changed N/A YoY), and the FY2025 annual result was $25.8 million, down 23.46% from the prior year.
- Equity Average was little changed at -$42.0 million in Q4 2017 per SLGL's latest filing.
- Over five years, Equity Average peaked at -$42.0 million in Q4 2017 and troughed at -$42.0 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -42.02 Mn |